Pular para o conteúdo principal
Ranking Invest

ITCI - Intra-Cellular Therapies, Inc.

Segmento: HealthcareIntra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Análise Ranking Invest

Valuation estimado
$ 510.59 Mi
Último Balanço Atualizado: 4T2024

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 1.15 Bi

Dívida Líquida

-$ 289.97 Mi

L4T

-$ 74.68 Mi

MM4T

-11.02%

Indicadores Básicos

ROE

-6.50%

Índices de Previsibilidade

Receita Líquida

F0.62

Lucro

B0.22

Margem

D0.57

Índices de Tendência

Receita Líquida

A11.76

Lucro

A10.16

Margem

A10.69

Índices de Endividamento

DIV/PAT

-0.25

DIV/L4T

3.88

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.